Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 17, Issue 9, Pages 1053-1063Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2017.1346607
Keywords
Angiogenesis; anti-angiogenic therapy; endoglin; endothelium; proangiogenic therapy
Funding
- Ministerio de Economia y Competitividad of Spain [SAF2010-15881, SAF2013-45784-R]
- Junta de Castilla y Leon [GR100]
- Fundacion Renal Inigo Alvarez de Toledo
- Kidney Research Network REDINREN [RD06/0016/0013, RD12/0021/0032, RD016/0009/0025]
- Institute de Salud Carlos III [PI16/00460]
- FEDER
- Ministerio de Economia y Competitividad of Spain
Ask authors/readers for more resources
Introduction: Alterations in the process of angiogenesis, either by excess or by defect, are present in different common pathologies. For this reason, great efforts are being made toward the development of pro- and anti-angiogenic therapies. Since endoglin levels are enhanced in tissues undergoing angiogenesis, and changes in its expression lead to alterations in vessel formation, endoglin has become an ideal target for these types of therapies.Areas covered: In this review, the role of endoglin in angiogenesis is summarized. In addition, the authors review pro- and anti-angiogenic therapies that are currently being used and new approaches that target endoglin. The article includes therapies that are both in preclinical and clinical development.Expert opinion: Endoglin is a very good target for anti-angiogenic therapy, as demonstrated by the positive results obtained with anti-endoglin antibodies. However, although endoglin in pro-angiogenic therapies has been successful in vitro, its use has not yet reached clinical settings. Moreover, the authors believe that establishing the exact role of endoglin in angiogenesis is essential and that this should be the next step in this field in the coming years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available